United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

genesis pharmaceuticals ltd - ibandronic sodium monohydrate - tablet - 150mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

consilient health ltd - ibandronic sodium monohydrate - tablet - 150mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

consilient health ltd - ibandronic sodium monohydrate - tablet - 50mg

Bangladesh - English - DGDA (Directorate General of Drug Administration)

popular pharmaceuticals ltd. - ibandronic acid - tablet - 150 mg

United States - English - NLM (National Library of Medicine)

tagi pharma, inc. - ibandronate sodium (unii: j12u072ql0) (ibandronic acid - unii:umd7g2653w) - ibandronate sodium injection is indicated for the treatment of osteoporosis in postmenopausal women. in postmenopausal women with osteoporosis, ibandronate sodium increases bone mineral density (bmd) and reduces the incidence of vertebral fractures [see clinical studies(14)] . the safety and effectiveness of ibandronate sodium for the treatment of osteoporosis are based on clinical data of one year duration. the optimal duration of use has not been determined. all patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. patients at low-risk for fracture should be considered for drug discontinuation after 3 to 5 years of use. patients who discontinue therapy should have their risk for fracture re-evaluated periodically. ibandronate sodium is contraindicated in patients with the following conditions: hypocalcemia [see warnings and precautions (5.1) ] known hypersensitivity to ibandronate sodium injection or to any of

European Union - English - EMA (European Medicines Agency)

atnahs pharma netherlands b.v. - ibandronic acid - hypercalcemia; breast neoplasms; neoplasm metastasis; fractures, bone - drugs for treatment of bone diseases - bondronat is indicated for:prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases;treatment of tumour-induced hypercalcaemia with or without metastases.

European Union - English - EMA (European Medicines Agency)

pharmathen s.a. - ibandronic acid - hypercalcemia; fractures, bone; neoplasm metastasis; breast neoplasms - drugs for treatment of bone diseases - concentrate for solution for infusion prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases. treatment of tumour-induced hypercalcaemia with or without metastases. film-coated tablets prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases.,

Malta - English - Medicines Authority

actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - ibandronic acid - film-coated tablet - ibandronic acid 150 mg - drugs for treatment of bone diseases

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - sodium ibandronate monohydrate 168,79 mg - eq. ibandronic acid 150 mg - film-coated tablet - 150 mg - ibandronate sodium monohydrate - ibandronic acid

Ireland - English - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - ibandronate sodium monohydrate - film-coated tablet - 150 milligram(s) - bisphosphonates; ibandronic acid